Reading the "T" Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple Myeloma - PubMed
7 hours ago
- #multiple myeloma
- #bispecific antibodies
- #prognostic models
- Frenking and colleagues developed three risk score models to predict outcomes of bispecific T-cell engager (TCE) therapy in multiple myeloma.
- The models predict hematotoxicity, infections, response rates, and survival.
- Validation was done using retrospective real-world data from 278 patients.
- The risk scores can be calculated using routine blood tests.
- These models aim to improve the efficacy and safety of TCE therapy.